Detalles de la búsqueda
1.
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial.
Blood
; 141(14): 1666-1674, 2023 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564045
2.
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Br J Haematol
; 201(5): 845-850, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36895158
3.
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.
Br J Haematol
; 201(2): 267-279, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541152
4.
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.
Br J Haematol
; 197(2): 171-187, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35020191
5.
Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials.
Blood
; 136(9): 1091-1104, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32438407
6.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32731259
7.
Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.
Haematologica
; 107(1): 231-242, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33297668
8.
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med
; 18(1): e1003454, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33428632
9.
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Br J Haematol
; 193(3): 551-555, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32524584
10.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Br J Haematol
; 193(4): 750-760, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33650100
11.
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial.
Br J Haematol
; 192(5): 853-868, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32656799
12.
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive).
Haematologica
; 106(10): 2694-2706, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910333
13.
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
Haematologica
; 106(7): 1957-1967, 2021 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32499244
14.
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.
Blood
; 131(9): 974-981, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29284595
15.
Subclonal TP53 copy number is associated with prognosis in multiple myeloma.
Blood
; 132(23): 2465-2469, 2018 12 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373884
16.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30181174
17.
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 20(1): 57-73, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30559051
18.
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 25(3): e89-e97, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30408566
19.
Neutral tumor evolution in myeloma is associated with poor prognosis.
Blood
; 130(14): 1639-1643, 2017 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28827410
20.
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Haematologica
; 104(7): 1440-1450, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30733268